Recurrent Melanoma Recruiting Phase 2 Trials for Talimogene laherparepvec (DB13896)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02965716Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV MelanomaTreatment